NCT06344793Completed
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
A Multi-center Study of the Clinical Outcomes Between Initial CDK 4/6 Inhibitor Plus Endocrine Therapy and Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer in Real World Practice
Source: ClinicalTrials.gov · Last updated 28 Jul 2025
Brief summary (registry, in English)
A multi-center, real world study to evaluate the clinical outcomes between initial CDK 4/6 Inhibitor plus endocrine therapy and initial chemotherapy in HR positive, HER2 negative unresectable or metastatic breast cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 608 (actual)
- First submitted
- 28 Mar 2024
- Start date
- 20 May 2023
- Primary completion date
- 1 Oct 2024
- Lead sponsor
- Fudan University
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06344793
What you commit to
- Study type: Observational
- Participants enrolled: 608
- From 20 May 2023 to the primary completion date, 1 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Medical history was incomplete.
Who the study is looking for
- age \>= 18 years old;
- Patients who were diagnosed as HR Positive, HER2 Negative recurrent unresectable (local or regional) or stage IV (M1) breast cancer between June 2020 to October 2023;
- Received CDK4/6 inhibitor plus endocrine treatment or chemotherapy as first-line therapy for at least one cycle;
- Complete medical history was available.
Age in the registry: 18 years to 75 years · Sex: Female
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.